A

Aurinia Pharmaceuticals
D

AUPH

8.93000
USD
-0.14
(-1.49%)
مغلق
حجم التداول
63,523
الربح لكل سهم
1
العائد الربحي
-
P/E
33
حجم السوق
1,206,481,417
أصول ذات صلة
A
ACAD
0.190
(0.82%)
23.250 USD
AMGN
AMGN
-2.01
(-0.65%)
306.66 USD
A
ARRY
0.22500
(3.37%)
6.90000 USD
C
CRIS
0.01500
(0.82%)
1.84000 USD
E
ESPR
0.00500
(0.34%)
1.49500 USD
MRK
MRK
0.570
(0.68%)
84.730 USD
V
VKTX
0.960
(2.87%)
34.420 USD
VRTX
VRTX
-2.89
(-0.61%)
469.58 USD
المزيد
الأخبار المقالات

العنوان: Aurinia Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.